Nectar Lifesciences (NECLIFE) | Stock Overview & Key Data
Nectar Lifesciences Performance Comparison
Stock Range
Today's Range
Low: ₹14.11
High: ₹14.11
on October 1, 2025
52 Week Range
Low: ₹13.05
High: ₹45.28
on August 8, 2025
on October 4, 2024
All-Time High: ₹60.90 on December 7, 2015
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR3.3B
EPS
-8.02
P/E Ratio (TTM)
24.67
Forward P/E
4.85
P/B Ratio
0.34
PEG Ratio
-0.01
Div. Yield
N/A
ROE
-11.89%
Beta
0.580
Debt to Equity
60.87
Financial Highlights
Profitability
Gross Margin
6.10%
Operating Margin
-27.94%
Profit Margin
-11.30%
Returns and Earnings
Return on Assets (TTM)
-5.55%
Return on Equity (TTM)
-11.89%
EBITDA
INR-1.3B
Net Income (TTM)
INR-1.8B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR70.98
Quarterly Revenue Growth (YoY)
-21.80%
Quarterly Earnings Growth (YoY)
-21.79%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Nectar Lifesciences NECLIFE | 3.25B Small-cap | -6.12% | -0.77% | -37.65% | -41.43% | -64.50% | -66.36% | -37.01% | -35.13% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | 2.80% | 3.33% | -2.89% | -7.84% | -13.69% | -14.60% | 70.78% | 218.03% |
| Divi's Laboratories DIVISLAB | 1.61T Large-cap | 3.10% | -4.83% | -14.69% | 1.79% | -3.41% | 8.12% | 57.02% | 83.89% |
| Suven Life Sciences SUVEN | 48.20B Small-cap | -0.17% | -3.10% | -15.83% | 58.82% | 63.15% | 46.77% | 186.97% | 307.88% |
| Sequent Scientific SEQUENT | 48.13B Small-cap | -8.42% | 9.29% | -3.35% | 37.17% | 0.89% | -10.14% | 69.59% | 19.72% |
| Aarti Drugs AARTIDRUGS | 44.55B Small-cap | 4.61% | 0.24% | 1.59% | 41.06% | 7.93% | -4.79% | -0.89% | -50.06% |
Ownership & Short Interest
Insider Ownership
48.79%
Institutional Ownership
0.03%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
123K
Average 90-Day Volume
279K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is NECLIFE's 52-week high and low?
- In the last 52 weeks, Nectar Lifesciences reached a high of ₹45.28 (on October 4, 2024) and a low of ₹13.05 (on August 8, 2025).
- What is the market cap and P/E ratio for NECLIFE?
- Curious about Nectar Lifesciences's size and valuation? Its market capitalization stands at 3.25B. When it comes to valuation, the P/E ratio (trailing twelve months) is 24.67, and the forward P/E (looking ahead) is 4.85.
- Does NECLIFE pay dividends? If so, what's the yield?
- As for dividends, Nectar Lifesciences isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Nectar Lifesciences's main competitors or similar companies to consider before investing?
When looking at Nectar Lifesciences, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -14.60% 70.78% Divi's Laboratories
DIVISLAB1.61T Healthcare Drug Manufacturers - Specialty & Generic 8.12% 57.02% Suven Life Sciences
SUVEN48.20B Healthcare Drug Manufacturers - Specialty & Generic 46.77% 186.97% Sequent Scientific
SEQUENT48.13B Healthcare Drug Manufacturers - Specialty & Generic -10.14% 69.59% Aarti Drugs
AARTIDRUGS44.55B Healthcare Drug Manufacturers - Specialty & Generic -4.79% -0.89% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Nectar Lifesciences Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Nectar Lifesciences's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -11.89%, the Debt to Equity ratio from the most recent quarter is 60.87, and its Gross Profit Margin stands at 6.10%.
- What is the recent revenue and earnings growth for NECLIFE?
- Looking at Nectar Lifesciences's growth, its revenue over the trailing twelve months (TTM) was INR16B. Compared to the same quarter last year (YoY), quarterly revenue grew by -21.80%, and quarterly earnings saw a YoY growth of -21.79%.
- How much of NECLIFE stock is held by insiders and institutions?
- Wondering who owns Nectar Lifesciences stock? Company insiders (like executives and directors) hold about 48.79% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.03%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.